title: Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
abstract: Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.
authors.affiliation: Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom. clifford.leen@ed.ac.uk
authors.forename: Clifford
authors.initials: C
authors.lastname: Leen
authors.forename: Cynthia
authors.initials: C
authors.lastname: Wat
authors.forename: Keith
authors.initials: K
authors.lastname: Nieforth
mesh_terms: D000328:Adult; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics*; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism*; D008297:Male; D010446:Peptide Fragments / Q000493:pharmacokinetics*
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide